高血压削弱冠状动脉钙化评分在低危患者中的预后价值
本研究纳入772例疑似缺血症状的门诊患者,排除52例60天内血运重建者,对720例随访38.1±17.4个月。结果显示高血压与不良结局强相关(未调整HR 6.5),且高血压患者非钙化斑块患病率翻倍(30.2% vs 14.3%)。CACS>400仅能预测正常血压者的MACE(HR 10.6),对高血压患者无预测价值(HR 1.3)。
要点
- 高血压患者非钙化斑块患病率显著高于正常血压者(30.2% vs 14.3%)。
- CACS>400仅预测正常血压者MACE(HR 10.6),高血压者无预测价值(HR 1.3)。
- 零钙化评分不能消除MACE风险,13/27例MACE患者钙化评分为0且均有高血压。
核心结论
- 在低危稳定心血管症状患者中,CTCA较CACS提供额外的预后信息,CACS(包括>400)低估高血压患者的心血管风险,可能与高血压患者非钙化斑块患病率增加有关。
研究设计与样本
- 单中心回顾性队列研究,连续纳入772例疑似缺血症状的门诊患者,排除52例(6.7%)60天内血运重建者,最终720例随访38.1±17.4个月。
主要发现
- 随访期间27例(3.8%)发生晚期(60天后)主要不良心血管事件(MACE)。
临床怎么用
- 对低危稳定心血管症状患者,CTCA可提供优于CACS的预后信息,尤其高血压患者应优先考虑CTCA评估。
- 高血压患者即使CACS>400或钙化评分为0,也不能据此排除风险,需结合CTCA评估非钙化斑块和狭窄。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In outpatients with suspected ischaemic symptoms, we investigated the impact of risk factor profile on the prognostic value of coronary artery calcium scoring (CACS) and CT coronary angiography (CTCA). METHODS: 772 consecutive patients underwent CACS and CTCA; 52 patients (6.7%) with significant coronary artery lesions underwent revascularisation within 60 days and were excluded. 720 remaining patients were followed up for 38.1±17.4 months. RESULTS: Late presentation (after 60 days) major adverse cardiovascular events (MACEs) were recorded in 27 patients (3.8%). Hypertension was strongly associated with adverse outcomes (unadjusted HR 6.5 (2.9 to 14), p<0.001), and hypertensive patients had double the prevalence of non-calcified plaque versus normotensive individuals (30.2% vs 14.3%, p<0.001). Adjusting for confounders, severe stenosis at CTCA was predictive of MACE for normotensive and hypertensive patients (HR 9.6 (2.8 to 43.1), p<0.001, and HR 6.2 (2.4 to 16.1), p<0.001, respectively). CACS alone was not predictive of MACE throughout the cohort (HR 1.001 (0.9997 to 1.001), p=0.36) and when adjusting for confounders, a cut-off of CACS>400 predicted MACE in normotensive individuals (HR 10.6 (2.41 to 49.3), p<0.001) but not in hypertensive individuals (HR 1.3 (0.5 to 3.6), p=0.56). Zero calcium score did not mitigate the risk of MACE (HR 0.84 (0.39 to 1.8), p=0.65) and 13/27 patients (48.1%) who suffered MACE had a 0 calcium score; all had hypertension. CONCLUSIONS: In low-risk patients with stable cardiovascular symptoms, CTCA provides important additive prognostic information over CACS, and CACS (including CACS>400) underestimated cardiovascular risk in patients with hypertension. This may relate to the increased prevalence of non-calcified plaque in these individuals.
引用
- Maclean E, Sehmi J, Kanaganayagam G, et al. Hypertension attenuates the prognostic value of coronary artery calcification scoring in low-risk patients. Heart. 2021. PMID: 33109707. doi:10.1136/heartjnl-2020-317399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。